Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals-Reference-Cited by-同舟云学术

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals

Author:

Møller Anaïs M J¹²³⁴,Delaisse Jean‐Marie¹²³⁵⁶,Olesen Jacob B¹³,Bechmann Troels²⁷,Madsen Jonna S²⁴,Søe Kent¹²³⁵⁶^ORCID

Affiliation:

1. Clinical Cell Biology Lillebaelt Hospital, University Hospital of Southern Denmark Vejle Denmark

2. Department of Regional Health Research University of Southern Denmark Vejle Denmark

3. Clinical Cell Biology, Department of Pathology Odense University Hospital Odense Denmark

4. Department of Clinical Biochemistry and Immunology Lillebaelt Hospital, University Hospital of Southern Denmark Vejle Denmark

5. Department of Clinical Research University of Southern Denmark Odense Denmark

6. Department of Molecular Medicine University of Southern Denmark Odense Denmark

7. Department of Oncology Lillebaelt Hospital, University Hospital of Southern Denmark Vejle Denmark

Funder

Aase og Ejnar Danielsens Fond

Syddansk Universitet

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

Reference64 articles.

2. Osteoporosis: a review of treatment options;Tu KN;P & T.,2018

3. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases;Ibrahim A;Clin Cancer Res.,2003

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献